Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (University of Alberta, f4dd7b)
- Development stage
- Unknown
- Lead developer
- University of Alberta
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplant (FMT) is an investigational live biotherapeutic product being studied by the University of Alberta for the treatment of hepatic encephalopathy (HE). The therapy involves transferring fecal bacteria from a healthy donor to a patient to restore a healthy gut microbiome. In patients with liver cirrhosis, an imbalanced gut microbiome (dysbiosis) can lead to increased production of neurotoxins, such as ammonia, which contribute to the neuropsychiatric symptoms of HE. The pilot study conducted by the University of Alberta aimed to determine if FMT could reverse HE in cirrhotic patients who had breakthrough episodes despite standard maintenance therapy with lactulose and/or rifaximin.
- Other names
- FMTfecal transplantstool transplant
Beyond the preview
Go deeper on fecal microbiota transplant (University of Alberta, f4dd7b).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (University of Alberta, f4dd7b).